The following are highlights from a case discussion, which was moderated by the Course Director, Quan Dong Nguyen, MD, MSc. The faculty reviewed 3 case studies and discussed their different approaches to managing the treatment of each patient. They also fielded questions from audience members about their management suggestions and the potential US Food and Drug Administration approval of aflibercept, which was not approved at the time of this discussion. In addition, the 2-year CATT (Comparison of Age-Related Macular Degeneration Treatments Trials) results and 1-year IVAN (Inhibit Vascular Endothelial Growth Factor in Age-Related Choroidal Neovascularization) results were not released at the time this discussion took place.
ASJC Scopus subject areas